Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia

Abstract

IntroductionFindings on the association between statin therapy and Parkinson's disease (PD) occurrence have been inconsistent. This study aimed to identify the association between statin use and PD in participants with a history of hyperlipidemia or blood cholesterol >200 in a Korean population to exclude nonstatin users owing to normal lipid values. MethodsWe conducted a nested case-control analysis using the Korean National Health Insurance Service-National Sample Cohort assessed between 2002 and 2015. We identified 3026 PD cases. A total of 12,104 controls were then individually matched by age, sex, income, and region of residence at a ratio of 1:4. Potential confounders comprised basic demographic factors, lifestyle factors, various medical conditions and comorbidities. A conditional/unconditional logistic regression method was applied. ResultsCompared with statin use for <6 months, adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for 6–12 months of statin use and ≥12 months of statin use were 1.03 (0.92–1.15) and 1.61 (1.35–1.93) after adjustment for confounders, respectively (P = 0.664 and P < 0.001). In analyses according to statin solubility, only the association between lipophilic statin use for ≥12 months and PD maintained statistical significance, with an aOR of 1.64 (95% CI = 1.34–2.01, P < 0.001). These relations were consistent in subgroup analyses by covariates. ConclusionsStatin use for more than 12 months was associated with a higher probability of PD in the Korean population with hyperlipidemia. This probability was significant for lipophilic statins but not hydrophilic statins.